(Q43060762)

English

Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer

scientific article published on 18 May 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

author name string

Vicky S Sabine

1

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

E Jane Macaskill

3

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

Lorna Renshaw

4

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

Jeremy S Thomas

5

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

J Michael Dixon

6

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

John M S Bartlett

7

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

language of work or name

0 references

publication date

18 May 2010

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

122

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

419-428

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

https://scigraph.springernature.com/pub.10.1007/s10549-010-0928-6

0 references

The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

AKT activation predicts outcome in breast cancer patients treated with tamoxifen

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

Akt kinases in breast cancer and the results of adjuvant therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

The role of mTOR in the management of solid tumors: an overview

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

Targeted therapies in breast cancer: where are we now?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

PI3K/Akt/mTOR pathway as a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

Observer variation in immunohistochemical analysis of protein expression, time for a change?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

Bioconductor: open software development for computational biology and bioinformatics

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

beadarray: R classes and methods for Illumina bead-based data.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

Adjusting batch effects in microarray expression data using empirical Bayes methods

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

Significance analysis of microarrays applied to the ionizing radiation response

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

Diagnosis of multiple cancer types by shrunken centroids of gene expression

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

Cluster analysis and display of genome-wide expression patterns

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

Correcting for intra-experiment variation in Illumina BeadChip data is necessary to generate robust gene-expression profiles

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

Oligonucleotide microarray analysis of estrogen receptor alpha-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

FRAP-p70s6K signaling is required for pancreatic cancer cell proliferation

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

Systems-level analysis of ErbB4 signaling in breast cancer: a laboratory to clinical perspective

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

Gene-expression signatures in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

Clinical application of the 70-gene profile: the MINDACT trial

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

Predicting response and resistance to endocrine therapy: profiling patients on aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

A consensus prognostic gene expression classifier for ER positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0928-6

21 January 2018

Identifiers

10.1007/S10549-010-0928-6

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43060762&oldid=1979153109"